Nestle recalls DiGiorno pizza nationwide following consumer complaint

Nestle USA Inc. of Schaumburg, IL, is recalling almost 14 tons of frozen DiGiorno Crispy Pan Crust pepperoni pizza because of misbranding and undeclared allergens, the U.S. Department of Agriculture’s Food Safety and Inspection Service (FSIS) announced today. The product contains textured soy protein, a known allergen, which is not declared on the product label.

The frozen pepperoni pizza product carton may actually contain frozen three meat pizza, which contains textured soy protein. The pizza products were produced on June 30, 2021. The best-buy date is March of 2022.

“FSIS is concerned that some product may be in consumers’ freezers. Consumers who have purchased these products are urged not to consume them. These products should be thrown away or returned to the place of purchase,” according to the recall announcement.

Consumers view the labels here and use the following information to determine whether they have the recalled pizza in their homes.

  • 26-oz. carton containing “DIGIORNO PEPPERONI CRISPY PAN CRUST” with lot code 1181510721 and “Best Buy” date of MAR2022 on the label.

The products subject to recall bear establishment number “EST. 1682A” printed inside the USDA mark of inspection. Establishment 1682A is Nation Pizza Products Limited, which is owned by Nestle USA, Inc. These items were shipped to retail locations and distribution centers nationwide.

 The problem was discovered after the firm received a consumer complaint that a three meat pizza was in a carton labeled as pepperoni pizza.

There have been no confirmed reports of adverse allergic reactions related to consumption of the pizza. Anyone concerned about an injury or illness should contact a healthcare provider.

FSIS routinely conducts recall effectiveness checks to verify recalling firms notify their customers of the recall and that steps are taken to make certain that the product is no longer available to consumers. When available, the retail distribution lists will be posted on the FSIS website at www.fsis.usda.gov/recalls.

Consumers with questions about the recall can contact Bonita Cleveland, Consumer Services Manager at Nestle USA, at 800-681-1676 or bonita.cleveland@us.nestle.com.

(To sign up for a free subscription to Food Safety News, click here.)

Note: This article have been indexed to our site. We do not claim ownership or copyright of any of the content above. To see the article at original source Click Here

Related Posts
Self-Replicating mRNA Vaccine for COVID Prevention thumbnail

Self-Replicating mRNA Vaccine for COVID Prevention

Please enable cookies. Error 1005 Ray ID: 8fce34ff4e0d3b22 • 2025-01-04 21:08:59 UTC What happened? The owner of this website (www.medscape.com) has banned the autonomous system number (ASN) your IP address is in (47583) from accessing this website. Was this page helpful? Thank you for your feedback! Cloudflare Ray ID: 8fce34ff4e0d3b22 • Your IP: 185.124.111.116 •
Read More
Weekend Warriors and Dementia; Iron Chelation and Alzheimer's; Neuro Drug Costs Rise thumbnail

Weekend Warriors and Dementia; Iron Chelation and Alzheimer’s; Neuro Drug Costs Rise

Neurology > General Neurology — News and commentary from the world of neurology and neuroscience by Judy George, Deputy Managing Editor, MedPage Today November 5, 2024 Longitudinal survey data from Mexico suggested that a so-called weekend warrior physical activity pattern was associated with a reduced risk of mild dementia. (British Journal of Sports Medicine) Also
Read More
How integrating AI and clinical decision support systems can help in the ER thumbnail

How integrating AI and clinical decision support systems can help in the ER

Deployment of artificial intelligence for point-of-care clinical decision support is in its nascency. Despite the media attention and proliferation of AI studies, translation to clinical practice is rare. Little evidence exists on best practices for deployment, particularly in emergency medicine. Emergency medicine serves as the frontline of healthcare and the integration of AI and clinical
Read More
Sotorasib Promising for KRAS–Related Vascular Malformations thumbnail

Sotorasib Promising for KRAS–Related Vascular Malformations

Dermatology > General Dermatology — Two patients had rapid symptom improvement and reductions in malformation volume by Mike Bassett, Staff Writer, MedPage Today July 18, 2024 Treating severe KRAS G12C-related arteriovenous malformations with sotorasib (Lumakras) appeared to be effective in a small French study. Two adult patients with the life-threatening condition who were treated with
Read More
Index Of News
Total
0
Share